TY - JOUR
T1 - Integrated single-cell analysis reveals distinct epigenetic-regulated cancer cell states and a heterogeneity-guided core signature in tamoxifen-resistant breast cancer
AU - Fang, Kun
AU - Ohihoin, Aigbe G.
AU - Liu, Tianxiang
AU - Choppavarapu, Lavanya
AU - Nosirov, Bakhtiyor
AU - Wang, Qianben
AU - Yu, Xue Zhong
AU - Kamaraju, Sailaja
AU - Leone, Gustavo
AU - Jin, Victor X.
N1 - Funding:
This project was partially supported by grants from NIH R01GM114142 and
Advancing A Healthier Wisconsin (AHW) Seed Grant.
Publisher Copyright:
© The Author(s) 2024.
PY - 2024/11/18
Y1 - 2024/11/18
N2 - Background: Inter- and intra-tumor heterogeneity is considered a significant factor contributing to the development of endocrine resistance in breast cancer. Recent advances in single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) allow us to explore inter- and intra-tumor heterogeneity at single-cell resolution. However, such integrated single-cell analysis has not yet been demonstrated to characterize the transcriptome and chromatin accessibility in breast cancer endocrine resistance. Methods: In this study, we conducted an integrated analysis combining scRNA-seq and scATAC-seq on more than 80,000 breast tissue cells from two normal tissues (NTs), three primary tumors (PTs), and three tamoxifen-treated recurrent tumors (RTs). A variety of cell types among breast tumor tissues were identified, PT- and RT-specific cancer cell states (CSs) were defined, and a heterogeneity-guided core signature (HCS) was derived through such integrated analysis. Functional experiments were performed to validate the oncogenic role of BMP7, a key gene within the core signature. Results: We observed a striking level of cell-to-cell heterogeneity among six tumor tissues and delineated the primary to recurrent tumor progression, underscoring the significance of these single-cell level tumor cell clusters classified from scRNA-seq data. We defined nine CSs, including five PT-specific, three RT-specific, and one PT-RT-shared CSs, and identified distinct open chromatin regions of CSs, as well as a HCS of 137 genes. In addition, we predicted specific transcription factors (TFs) associated with the core signature and novel biological/metabolism pathways that mediate the communications between CSs and the tumor microenvironment (TME). We finally demonstrated that BMP7 plays an oncogenic role in tamoxifen-resistant breast cancer cells through modulating MAPK signaling pathways. Conclusions: Our integrated single-cell analysis provides a comprehensive understanding of the tumor heterogeneity in tamoxifen resistance. We envision this integrated single-cell epigenomic and transcriptomic measure will become a powerful approach to unravel how epigenetic factors and the tumor microenvironment govern the development of tumor heterogeneity and to uncover potential therapeutic targets that circumvent heterogeneity-related failures.
AB - Background: Inter- and intra-tumor heterogeneity is considered a significant factor contributing to the development of endocrine resistance in breast cancer. Recent advances in single-cell RNA sequencing (scRNA-seq) and single-cell ATAC sequencing (scATAC-seq) allow us to explore inter- and intra-tumor heterogeneity at single-cell resolution. However, such integrated single-cell analysis has not yet been demonstrated to characterize the transcriptome and chromatin accessibility in breast cancer endocrine resistance. Methods: In this study, we conducted an integrated analysis combining scRNA-seq and scATAC-seq on more than 80,000 breast tissue cells from two normal tissues (NTs), three primary tumors (PTs), and three tamoxifen-treated recurrent tumors (RTs). A variety of cell types among breast tumor tissues were identified, PT- and RT-specific cancer cell states (CSs) were defined, and a heterogeneity-guided core signature (HCS) was derived through such integrated analysis. Functional experiments were performed to validate the oncogenic role of BMP7, a key gene within the core signature. Results: We observed a striking level of cell-to-cell heterogeneity among six tumor tissues and delineated the primary to recurrent tumor progression, underscoring the significance of these single-cell level tumor cell clusters classified from scRNA-seq data. We defined nine CSs, including five PT-specific, three RT-specific, and one PT-RT-shared CSs, and identified distinct open chromatin regions of CSs, as well as a HCS of 137 genes. In addition, we predicted specific transcription factors (TFs) associated with the core signature and novel biological/metabolism pathways that mediate the communications between CSs and the tumor microenvironment (TME). We finally demonstrated that BMP7 plays an oncogenic role in tamoxifen-resistant breast cancer cells through modulating MAPK signaling pathways. Conclusions: Our integrated single-cell analysis provides a comprehensive understanding of the tumor heterogeneity in tamoxifen resistance. We envision this integrated single-cell epigenomic and transcriptomic measure will become a powerful approach to unravel how epigenetic factors and the tumor microenvironment govern the development of tumor heterogeneity and to uncover potential therapeutic targets that circumvent heterogeneity-related failures.
KW - Breast tumor heterogeneity
KW - Epigenetic-regulated cancer cell states
KW - Single-cell analysis
KW - Antineoplastic Agents, Hormonal/pharmacology
KW - Humans
KW - Epigenesis, Genetic
KW - Transcriptome
KW - Bone Morphogenetic Protein 7/genetics
KW - Gene Expression Regulation, Neoplastic/drug effects
KW - Genetic Heterogeneity
KW - Drug Resistance, Neoplasm/genetics
KW - Cell Line, Tumor
KW - Female
KW - Breast Neoplasms/genetics
KW - Single-Cell Analysis
KW - Tamoxifen/pharmacology
UR - http://www.scopus.com/inward/record.url?scp=85209564467&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/39558215/
U2 - 10.1186/s13073-024-01407-3
DO - 10.1186/s13073-024-01407-3
M3 - Article
C2 - 39558215
AN - SCOPUS:85209564467
SN - 1756-994X
VL - 16
JO - Genome Medicine
JF - Genome Medicine
IS - 1
M1 - 134
ER -